Regulatory Frameworks in Modern Clinical Trials: Challenges, Gaps, and Future Directions

Clinical trials have undergone substantial transformation over the past decade, driven by innovations such as decentralized trial models, adaptive designs, and the incorporation of real-world data. While these developments have enhanced efficiency and patient accessibility, they have simultaneously introduced complex regulatory challenges. Existing regulatory frameworks often struggle to adequately address these evolving methodologies, particularly in ensuring data integrity, patient safety, and consistent oversight.
This review critically examines the current regulatory landscape governing modern clinical trials, highlighting key challenges and gaps in existing systems. Real-world examples are discussed to illustrate regulatory limitations and practical implications. The paper further explores future directions aimed at strengthening regulatory oversight while maintaining flexibility for innovation. A balanced approach is essential to ensure that advancements in clinical research do not compromise ethical standards or patient safety.

Clinical trials; Regulatory frameworks

1. Chow SC, Chang M. Adaptive design methods in clinical trials – a review. Orphanet J Rare Dis. 2008;3:11. doi:10.1186/1750-1172-3-11 [Google Scholar] [Crossref]

2. Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: hype and hypothesis. Clin Pharmacol Ther. 2018;104(1):42–52. doi:10.1002/cpt.966 [Google Scholar] [Crossref]

3. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375:2293–2297. doi:10.1056/NEJMsb1609216 [Google Scholar] [Crossref]

4. International Council for Harmonisation (ICH). Guideline for Good Clinical Practice E6(R2). 2016. [Google Scholar] [Crossref]

5. U.S. Food and Drug Administration. Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards. 2020. [Google Scholar] [Crossref]

6. European Medicines Agency. Guideline on computerized systems and electronic data in clinical trials. 2023. [Google Scholar] [Crossref]

7. Getz KA, Campo RA. Trial design complexity. Nat Rev Drug Discov. 2017;16:307. doi:10.1038/nrd.2017.65 [Google Scholar] [Crossref]

8. Thiers FA, Sinskey AJ, Berndt ER. Globalization of clinical trials. Nat Rev Drug Discov. 2008;7:13–14. doi:10.1038/nrd2441 [Google Scholar] [Crossref]

9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi:10.1056/NEJMoa2034577 [Google Scholar] [Crossref]

10. Booth CM, Karim S, Mackillop WJ. Real-world data in oncology. Nat Rev Clin Oncol. 2019;16:312–325. doi:10.1038/s41571-018-0117-9 [Google Scholar] [Crossref]

11. Dorsey ER, Topol EJ. Telehealth in clinical research. N Engl J Med. 2016;375:154–161. doi:10.1056/NEJMra1601705 [Google Scholar] [Crossref]

• Evaluation of C-Peptide in Breast Cancer Patients in Anambra State, Nigeria
• Serious Adverse Events in Oncology Trials: Novel Risk Assessment and Management Approaches